Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
California Director of Women's Health
StaffPointe, LLC - San Francisco , CA -
Wisonsin-General Surgeon
Ohrmund Employment Group - Cedarburg, WI -
Florida Noninvasive Cardiologist
StaffPointe, LLC - west , FL -
Arizona Nurse Practitioner
StaffPointe, LLC - southwest , AZ -
CA Nursing Direct. Medical/Telemetry
StaffPointe, LLC - San Francisco , CA
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
DOJ wants data on device payments
The Justice Department has launched an investigation into possible violations of anti-fraud and anti-kickback laws by leading medical device manufacturers. Medtronic, Guidant and St. Jude Medical are the focus of an investigation headed by the US attorney's office in Boston into possible improper payments made to doctors. With competition in the market for defibrillators and pacemakers intense, some critics have questioned the tactics companies use to win customers. In September, The New York Times reported on a Guidant program which paid cardiologists a $1,000 fee for implanting cardiac resynchronization therapy (CRT) devices and agreeing to complete a survey.
- see this article from The New York Times
PLUS: Guidant disclosed that it has received a subpoena in a separate investigation related to the recall of its Ventak Prizm and Contak Renewal defibrillators. Article
Related Stories
- FDA releases new defibrillator safety data
- Lawmakers want more data on heart devices
- FDA to monitor heart device safety
- Guidant releases more safety data, blames leads
- Panel critical of device maker; Medtronic may release data
- Guidant issues warning on faulty defibrillator
- Surgical device maker faces kickback investigation
- Medtronic sued over faulty defibrillator parts
- Medtronic faces more kickback accusations
- Boston Scientific announces recall, shares drop
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





